ArticleMolecular biology reports2025
DNMT1 targets SRD5A2 to induce mitochondrial homeostasis and EMT in urothelial cells of hypospadias.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aberrant methylation of mitochondrial genes as a link between oxidative phosphorylation dysregulation and the pathogenesis of hypospadias: a multiomics and clinical sample study.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHypospadias, a common congenital malformation of the urinary system, significantly impacts neonatal development. The enzyme Steroid 5 Alpha-Reductase 2 (SRD5A2), essential for androgen metabolism, is regulated epigenetically through methylation by DNA Methyltransferase 1 (DNMT1). This modification plays a critical role in cell differentiation and development. This study aims to reveal the molecular mechanisms by which DNMT1-mediated methylation of SRD5A2 affects the pathophysiology of hypospadias. METHODS AND
resultsWestern blot was utilized to quantify DNMT1 and SRD5A2 expression in primary urethral epithelial cells derived from rats afflicted with hypospadias. The regulation of SRD5A2 expression by DNMT1 methylation was confirmed through Chromatin Immunoprecipitation (ChIP) assays. Additionally, the influence of SRD5A2 on epithelial-mesenchymal transition (EMT), mitochondrial homeostasis, and energy metabolism was elucidated by further in vitro experiments, highlighting its potential biological impacts on hypospadias. DNMT1 methylation significantly upregulates SRD5A2 expression in urethral epithelial cells from hypospadias rats. Knockdown of DNMT1 and SRD5A2 elevated the levels of proteins associated with the cell cycle and mitochondrial function, and genes related to energy metabolism. Concurrently, these alterations inhibited EMT, promoted cellular proliferation and migration, arrested the cell cycle in the G1/S phase, and reduced apoptosis.
conclusionsDNMT1 and SRD5A2 exhibit elevated expression in hypospadias, with DNMT1 enhancing the expression of key proteins involved in the cell cycle, mitochondrial function, and energy metabolism through the methylation of SRD5A2. This inhibition of EMT and modulation of cellular functions suggest that SRD5A2 is a viable therapeutic target for hypospadias.
trial registrationNot applicable. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.